Suppr超能文献

糖尿病患者的尿路感染

Urinary tract infections in patients with diabetes.

作者信息

Stapleton Ann

机构信息

Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle 98195, USA.

出版信息

Am J Med. 2002 Jul 8;113 Suppl 1A:80S-84S. doi: 10.1016/s0002-9343(02)01062-8.

Abstract

Results of various epidemiologic studies suggest that bacteriuria and urinary tract infection (UTI) occur more commonly in women with diabetes than in women without this disease. Similar findings have been demonstrated for asymptomatic bacteriuria (ASB), with ASB being a risk factor for pyelonephritis and subsequent decline in renal function. Although ASB is not associated with serious health outcomes in healthy patients, further research needs to be undertaken regarding the impact of ASB in patients with diabetes. Patients with diabetes often have increased complications of UTI, including such rare complications as emphysematous cystitis and pyelonephritis, fungal infections (particularly Candida species), and increased severity and unusual manifestations (e.g., gram-negative pathogens other than Escherichia coli). Anatomic and functional abnormalities of the urinary tract are also associated with diabetes. Such abnormalities result in greater instrumentation of the urinary tract, thereby increasing the risk of secondary UTI. In addition, these abnormalities complicate UTI and require specialized treatment strategies. There is a greater likelihood of UTI affected by antimicrobial resistance or atypical uropathogens, and the risk of upper tract involvement is increased. Pre- and posttherapy urine cultures are therefore indicated. The initial choice of empiric antimicrobial therapy should be based on Gram stain and urine culture. Choice of antibiotic therapy should integrate local sensitivity patterns of the infecting organism. Fluoroquinolones are a reasonable empiric choice for many patients with diabetes. For seriously ill patients, including patients infected with Pseudomonas spp., such agents as imipenem, ticarcillin-clavulanate, and piperacillin-tazobactam may also be considered. Treatment of ASB in patients with diabetes is often recommended to prevent the risk of symptomatic UTI. However, the management of ASB in patients with diabetes is complex, with no single preferred approach.

摘要

各种流行病学研究结果表明,与非糖尿病女性相比,糖尿病女性菌尿症和尿路感染(UTI)更为常见。无症状菌尿症(ASB)也有类似的发现,ASB是肾盂肾炎和随后肾功能下降的危险因素。虽然ASB在健康患者中与严重健康后果无关,但需要进一步研究ASB对糖尿病患者的影响。糖尿病患者的UTI并发症往往增加,包括气肿性膀胱炎和肾盂肾炎等罕见并发症、真菌感染(尤其是念珠菌属),以及病情严重程度增加和表现异常(如除大肠杆菌外的革兰氏阴性病原体)。尿路的解剖和功能异常也与糖尿病有关。这些异常导致更多的尿路器械操作,从而增加继发性UTI的风险。此外,这些异常使UTI复杂化,需要专门的治疗策略。UTI受抗菌药物耐药性或非典型尿路病原体影响的可能性更大,上尿路受累的风险增加。因此,需要进行治疗前和治疗后的尿培养。经验性抗菌治疗的初始选择应基于革兰氏染色和尿培养。抗生素治疗的选择应综合考虑感染病原体的局部敏感性模式。氟喹诺酮类药物是许多糖尿病患者合理的经验性选择。对于重症患者,包括感染假单胞菌属的患者,也可考虑使用亚胺培南、替卡西林-克拉维酸和哌拉西林-他唑巴坦等药物。通常建议对糖尿病患者的ASB进行治疗,以预防有症状UTI的风险。然而,糖尿病患者ASB的管理很复杂,没有单一的首选方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验